General Principles - The purpose of the fundraising management measures is to standardize the management and use of funds raised by the company, protect investors' rights, and comply with relevant laws and regulations [1][2] - The board of directors is responsible for ensuring the effective implementation of these measures [1][2] Fundraising and Storage - The company must open a special account for fundraising, and funds should be stored in this account for centralized management [6][7] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank within one month of the funds being received [7][8] - The company must report to the Shanghai Stock Exchange within two trading days after signing the agreement [8] Use of Funds - Funds must be used according to the fundraising plan outlined in the issuance application documents [9][10] - If a fundraising project faces significant changes or delays, the company must reassess its feasibility and disclose the situation [10][11] - The company is prohibited from using funds for financial investments or providing funds to controlling shareholders or related parties [11][12] Management of Surplus Funds - Surplus funds should be used for ongoing projects, new projects, or share repurchases, and a specific plan for their use must be disclosed [16][17] - If surplus funds are used for cash management or temporary working capital, it must be approved by the board and disclosed [17][18] Changes in Fund Usage - Any changes in the use of funds must be approved by the board and disclosed to shareholders [19][20] - The company must conduct a feasibility analysis for new investment projects to ensure they enhance competitiveness and innovation [20][21] Supervision and Reporting - The company must maintain detailed records of fund usage and undergo regular internal audits [24][25] - The sponsor or independent financial advisor must conduct ongoing supervision and report any irregularities [29][30] Final Provisions - Any matters not covered by these measures will be governed by relevant national laws and regulations [30][31] - The board of directors is responsible for interpreting these measures [31][32]

炬芯科技股份有限公司 募集资金管理制度 第一章 总 则 第一条 为了加强对公司募集资金行为的管理，规范募集资金的使用，切实保护 广大投资者的利益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 海证券交易所科创板上市公司自律监管指引第1号——规范运作》《上市公司募集资金 监管规则》《上海证券交易所科创板股票上市规则》等相关法律法规规则以及《炬芯 科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定制定本制度。 第二条 本制度适用于公司通过发行股票或者其他具有股权性质的证券，向投资 者募集并用于特定用途的资金监管，但不包括公司实施股权激励计划募集的资金的 监管。 第三条 公司的董事会应当勤勉尽责，确保公司募集资金安全，不得操控公司擅 自或者变相改变募集资金用途。 第七条 公司应当在募集资金到账后一个月内与保荐机构或者独立财务顾问、存 放募集资金的商业银行（以下简称"商业银行"）签订三方监管协议并及时公告。相 关协议签订后，公司可以使用募集资金。该协议至少应当包括以下内容： （一）公司应当将募集资金集中存放于募集资金专户； （二）商业银行应当每月向公司提供募集资金专户银行对账单，并抄送保荐机 构 ...

Core Viewpoint - The company has completed the investment project of the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park" and plans to permanently supplement its working capital with the remaining raised funds, following the completion of the project and the approval of the board and shareholders [6][9][10]. Fundraising Overview - The company raised a total of RMB 758.8 million from its initial public offering, with a net amount of RMB 689.55 million after deducting issuance costs [1]. - The company established a special account for the management and use of the raised funds, ensuring compliance with regulatory requirements [2]. Investment Project Details - The company committed to invest RMB 276.46 million in the "High-Precision Small Power Testing Power Supply and Fuel Cell, Power Semiconductor Testing Equipment Production Base Construction Project" [2]. - The actual net amount raised was RMB 689.55 million, resulting in an excess of RMB 413.09 million after the planned investment [3]. Use of Excess Funds - The company decided to use RMB 120 million of the excess funds to permanently supplement working capital, which constitutes approximately 29.05% of the total excess funds [3][4]. - The remaining excess funds will be allocated to the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park Project," with a total investment of RMB 450 million, of which RMB 300 million will come from excess funds [4][5]. Project Completion and Surplus Funds - As of July 31, 2025, the project has completed its main construction and acceptance work, leading to the decision to conclude the project [6]. - The expected surplus funds amount to RMB 168.27 million, which includes interest and investment income, and will be used to permanently supplement working capital [8][9]. Impact on Company Operations - The decision to conclude the project and use surplus funds for working capital is aligned with the company's operational needs and long-term development strategy, enhancing cash flow and resource allocation [9][10]. - The company will maintain the special account for raised funds until all pending payments are settled, ensuring compliance with regulatory requirements [9]. Approval Process - The board of directors approved the proposal to conclude the investment project and use surplus funds on August 22, 2025, which will also require shareholder approval [10]. - The sponsor institution has confirmed that the decision complies with relevant regulations and is in the best interest of all shareholders [10][11].

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 部分募集资金投资项目延长实施期限的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为华厦眼科医 院集团股份有限公司（以下简称"华厦眼科"或"公司"）首次公开发行股票并在创业板上 市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资 金监管规则》 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规范性文件的规定， 对华厦眼科部分募集资金投资项目延长实施期限的事项进行了审慎核查，具体情况如下： 一、募集资金投资项目的基本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》 （证监许可〔2022〕2085 号）同意，公司首次公开发行人民币普通 股（A 股）6,000.00 万股，每股发行价为人民币 50.88 元，募集资金总额为人民币 净额为人民币 276,849.25 万元。上述募集资金已于 2022 年 10 月 28 日到账，容诚会计 师事务所（特殊普通合伙）对募集资金到位 ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-038 盈康生命科技股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 8 月 12 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第二十次会议的通知。会议于 场结合通讯的方式召开。会议应出席董事 9 人，实出席董事 9 人，董事谭丽霞、马 安捷以现场方式出席会议并投票表决，董事黄雯瑶、龚雯雯、潘绵顺、沈旭东、独 立董事杜媛、独立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票表决。本 次会议由董事长谭丽霞女士主持，公司的高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》等有 关法律、行政法规、部门规章、规范性文件及《盈康生命科技股份有限公司公司章 程》的规定。 二、董事会会议审议情况 （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 具体内容详见公司同日于巨潮资讯网（http://www.cninfo ...

格林美股份有限公司 募集资金管理办法（草案） （H 股发行并上市后适用） 第一章 总 则 第一条 为规范格林美股份有限公司（以下简称"公司"）募集资金的存放、 使用和管理，保证募集资金的安全，提高募集资金的使用效率，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上市公司募集资金监管规则》、 《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 下简称"《香港联交所上市规则》"）等法律、法规及规范性文件的规定，制定 本办法。 第二条 本办法所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励 计划募集的资金监管。 公司在香港证券市场通过发行 H 股募集资金管理按《香港联交所上市规 则》的相关规定执行。 第三条 募集资金到位后，公司应及时办理验资手续，由符合《证券法》规 定的会计师事务所出具验资报告。公司对募集资金的管理遵循专户存放、规范使 用、如实披露、严格管理的原则。 第四条 募集资金只能用于公司对外公布的募集资金投向的项目。公司董事 会应制定详细的资金使用计划，做到资金使用的规范公开和透明。 第五条 非经 ...

格林美股份有限公司 第一章 总 则 第一条 为规范格林美股份有限公司（以下简称"公司"）募集资金的存放、 使用和管理，保证募集资金的安全，提高募集资金的使用效率，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上市公司募集资金监管规则》、 《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 第二条 本办法所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励 计划募集的资金监管。 第三条 募集资金到位后，公司应及时办理验资手续，由符合《证券法》规 定的会计师事务所出具验资报告。公司对募集资金的管理遵循专户存放、规范使 用、如实披露、严格管理的原则。 第四条 募集资金只能用于公司对外公布的募集资金投向的项目。公司董事 会应制定详细的资金使用计划，做到资金使用的规范公开和透明。 第五条 非经公司股东会作出有效决议，任何人无权改变发行申请文件中承 诺的募集资金使用用途。 第六条 公司董事会应建立健全公司的募集资金管理制度并确保本制度的有 效实施，及时披露募集资金的使用情况，做到募集资金使用的公开、透明和规范。 第七 ...

Core Viewpoint - ST Dongshi (603377) has received an administrative regulatory decision from the Beijing Securities Regulatory Bureau, prompting the company to implement a comprehensive rectification plan to address identified issues [1][4]. Summary by Sections Regulatory Violations - On April 18, 2024, the company approved the temporary use of 106 million yuan of idle raised funds to supplement working capital for 12 months. However, due to multiple litigation cases and significant liquidity pressure, the company failed to repay the funds by the due date of April 17, 2025, violating relevant regulations [2]. Rectification Measures - The company is taking a multi-faceted approach to rectify the situation, including: - Accelerating communication with banks for new credit and extension plans - Liquidating inefficient idle assets and disposing of non-core fixed assets - Optimizing cash flow management and reducing expenses - Ensuring the repayment of 387 million yuan of non-operating funds by controlling shareholders and related parties - Actively seeking resolution with creditors through judicial mediation and negotiation - Hiring a professional legal team to manage long-standing or disputed debts [3]. Responsibility and Management - The rectification responsibility lies with the Chairman, General Manager, and Chief Financial Officer, with the board enforcing accountability for timely and effective rectification measures. The company asserts that the regulatory decision will not impact normal operations and emphasizes the importance of learning from this experience to protect the interests of the company and its investors [4].

Core Points - The company has approved a cash dividend distribution plan for the year 2024, proposing to distribute RMB 3.00 per 10 shares, totaling approximately RMB 32.97 million [3][4] - The company will use RMB 176.58 million of remaining raised funds to permanently supplement working capital, which accounts for 24.48% of the total raised funds [4][5] - The company has approved an increase in capital of RMB 20 million to its subsidiary, Dongguan Weikang Automotive Electronics Co., Ltd. [8] - The company has revised its articles of association and completed the necessary business registration changes [9] - The company has estimated that the total amount of daily related transactions with Dongguan Weifeng Interconnect Technology Co., Ltd. for 2025 will not exceed RMB 9.12 million [10] Financial Data - The company plans to distribute cash dividends based on a total share capital of 109,893,594 shares [3] - The cash dividend distribution for 2024 is expected to be completed by May 29, 2025 [4] - The company has adjusted the expected completion date for a project funded by raised funds from June 30, 2025, to September 30, 2025 [6] - The company has approved the use of up to RMB 700 million of idle self-owned funds for entrusted wealth management within a 12-month period [7]

Core Viewpoint - The company has approved the use of its own funds to pay for part of the investment project costs, which will later be replaced with raised funds, ensuring compliance with regulations and maintaining operational efficiency [23][29][31]. Group 1: Company Overview - The company is named Haishike Pharmaceutical Group Co., Ltd. and is publicly traded with the stock code 002653 [10]. - The company held its fifth board meeting on August 22, 2025, where all directors attended and approved the half-year report [2][5]. Group 2: Financial Data - The company raised a total of RMB 800 million through a non-public stock issuance, with a net amount of RMB 790.87 million after deducting issuance costs [11][23]. - The company has established a special account for the management of raised funds, ensuring compliance with regulatory requirements [12][23]. Group 3: Fund Usage - The company plans to use surplus funds from previous projects for new initiatives, including RMB 16.42 million for working capital and RMB 53.02 million for clinical research projects [25]. - The company has not changed the implementation location or method for any investment projects during the reporting period [14]. Group 4: Fund Management - The company has implemented a cash management strategy for temporarily idle raised funds, generating a cash return of RMB 1.39 million during the reporting period [15]. - The company has established a process for replacing its own funds with raised funds within six months, ensuring that the funds are used effectively [27][28]. Group 5: Compliance and Oversight - The board of directors has ensured that the use of self-funds for project payments complies with relevant regulations and does not affect the project's implementation [29][31]. - The company has received no negative feedback from its sponsor regarding the fund management practices [31].